We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

METhotrexate Therapy Effects in the Physical Capacity of Patients With ISchemic Heart Failure (METIS Trial) (METIS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00759811
First Posted: September 25, 2008
Last Update Posted: May 8, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Daniel Medeiros Moreira, Instituto de Cardiologia do Rio Grande do Sul
  Purpose
The aim of the study is to evaluate the efficacy of methotrexate to improve physical capacity in patients with symptomatic ischemic heart failure.

Condition Intervention Phase
Heart Failure Myocardial Ischemia Drug: Methotrexate Drug: Placebo Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: METhotrexate Therapy Effects in the Physical Capacity of Patients With ISchemic Heart Failure: Randomized Double-blind, Placebo-controlled Trial (METIS Trial)

Resource links provided by NLM:


Further study details as provided by Daniel Medeiros Moreira, Instituto de Cardiologia do Rio Grande do Sul:

Primary Outcome Measures:
  • Change in Physical Capacity Measured Using the 6-minute Walk Test Distance [ Time Frame: Baseline and 12 weeks ]
    The primary outcome of the study was the difference in 6MWT distance before and after the treatment (change in meters evaluated by t test).


Secondary Outcome Measures:
  • Improve in Heart Failure Functional Class Measured Using New York Heart Association [ Time Frame: 12 weeks ]
  • Improve in Quality of Life Measured Using the Brazilian Edition SF-36 [ Time Frame: 12 weeks ]
  • Reduction of Inflammatory Marker Measured Using C-reactive Protein Blood Levels [ Time Frame: 12 weeks ]
  • Incidence of All Cause Mortality, Hospitalization for Worsening Heart Failure, Myocardial Infarct, Stroke or Myocardial Revascularization Need [ Time Frame: 12 weeks ]
  • Incidence of Adverse Effects of the Treatment [ Time Frame: 12 weeks ]

Enrollment: 50
Study Start Date: December 2007
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Methotrexate
Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.
Drug: Methotrexate

Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.

All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks.

Other Names:
  • Rheumatrex
  • Trexall
Placebo Comparator: Placebo
Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.
Drug: Placebo

Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.

All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks.

Other Name: Control

Detailed Description:

Recent studies have showed the importance of proinflammatory mediators in the heart failure. However, there is a lack of benefit of therapies that tried to neutralize these mediators.

Methotrexate has adenosine-mediated anti-inflammatory effects in rheumatoid arthritis and psoriasis. Methotrexate limits infarct size via this adenosine-dependent mechanisms in heart of dogs (J Cardiovasc Pharmacol. 2004 Apr;43(4):574-9). A recent trial showed that this drug reduced proinflammatory mediators in patients with heart failure (Am Heart J. 2006 Jan;151(1):62-8).

These data suggest that methotrexate may improve physical capacity in patients ischemic heart failure reducing inflammation, but a randomized clinical trial is necessary to prove it.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Heart failure functional class measured using the New York Heart Association classification class II, III or IV
  • Left ventricular fraction <0.45 at the ventriculography
  • Angiographic coronary lesions higher than 50% or coronary lesion revascularized (coronary artery bypass or percutaneous transluminal coronary angioplasty)

Exclusion Criteria:

  • Myocardial infarction in the past four months
  • Coronary artery bypass or percutaneous transluminal coronary angioplasty in the past four months
  • Left ventricular disfunction diagnosed during a acute coronary syndrome
  • Those who require revascularization in the following 12 weeks
  • Hepatic disease (ALT and AST higher than the upper limit of the reference value)
  • Renal failure (plasma creatinine higher than 2.0mg/dl)
  • Alcoholism (20 doses per week or more)
  • Illegal drug use
  • Rheumatoid arthritis or other inflammatory diseases
  • Infectious disease
  • Neoplasm
  • Anemia (hematocrit lower than 30%)
  • Currently on any anti-inflammatory drugs
  • Difficulty in walking
  • Unable to understand/complete the 36-item Short Form health survey (SF-36)
  • Those who do not give informed consent
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00759811


Locations
Brazil
Instituto de Cardiologia do Rio Grande do Sul / Fundação Universitária de Cardiologia
Porto Alegre, Rio Grande do Sul, Brazil, 90620001
Sponsors and Collaborators
Instituto de Cardiologia do Rio Grande do Sul
Investigators
Study Director: Carlos AM Gottschall, MD MSc PhD Instituto de Cardiologia do Rio Grande do Sul
Principal Investigator: Daniel M Moreira, MD Instituto de Cardiologia do Rio Grande do Sul
Study Director: Jefferson L Vieira, MD Instituto de Cardiologia do Rio Grande do Sul
  More Information

Publications:
Responsible Party: Daniel Medeiros Moreira, MSc., Instituto de Cardiologia do Rio Grande do Sul
ClinicalTrials.gov Identifier: NCT00759811     History of Changes
Other Study ID Numbers: UP4062
First Submitted: September 24, 2008
First Posted: September 25, 2008
Results First Submitted: September 4, 2009
Results First Posted: May 8, 2013
Last Update Posted: May 8, 2013
Last Verified: March 2013

Keywords provided by Daniel Medeiros Moreira, Instituto de Cardiologia do Rio Grande do Sul:
Heart Failure
Myocardial Ischemia
Methotrexate
Inflammation
Anti-Inflammatory Agents
Inflammation Mediators

Additional relevant MeSH terms:
Heart Failure
Ischemia
Myocardial Ischemia
Coronary Artery Disease
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Vascular Diseases
Coronary Disease
Arteriosclerosis
Arterial Occlusive Diseases
Methotrexate
Folic Acid
Vitamin B Complex
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors
Hematinics